Akebia Therapeutics (NASDAQ: AKBA) and Progenics Pharmaceuticals (NASDAQ:PGNX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.
Earnings & Valuation
This table compares Akebia Therapeutics and Progenics Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Akebia Therapeutics||$177.98 million||3.42||-$135.74 million||($1.92)||-6.56|
|Progenics Pharmaceuticals||$11.70 million||51.42||-$51.01 million||($0.73)||-11.34|
This is a summary of recent ratings and recommmendations for Akebia Therapeutics and Progenics Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Akebia Therapeutics currently has a consensus price target of $23.50, suggesting a potential upside of 86.66%. Progenics Pharmaceuticals has a consensus price target of $13.75, suggesting a potential upside of 66.06%. Given Akebia Therapeutics’ higher probable upside, research analysts clearly believe Akebia Therapeutics is more favorable than Progenics Pharmaceuticals.
Volatility and Risk
Akebia Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Progenics Pharmaceuticals has a beta of 3.12, indicating that its stock price is 212% more volatile than the S&P 500.
Institutional and Insider Ownership
71.2% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 86.5% of Progenics Pharmaceuticals shares are owned by institutional investors. 8.7% of Akebia Therapeutics shares are owned by insiders. Comparatively, 3.6% of Progenics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Akebia Therapeutics and Progenics Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Progenics Pharmaceuticals beats Akebia Therapeutics on 8 of the 14 factors compared between the two stocks.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company’s vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.